Berg, Thomas: Chronische Hepatitis C - Therapeutische Strategien, molekulare Resistenzmechanismen und Relevanz neuer Hepatitis-assoziierter Viren -

62

Kapitel 6. Referenzen

1. Choo Q-L, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M . "Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome" . Science 1989 ; 244 : 359-362 .

2. Bradley DW, Maynard JE . "Etiology and natural history of post-transfusion and enterically transmitted non-A, non-B hepatitis" . Sem Liver Dis 1986 ; 6 : 56-66 .

3. European patent application (Europäisches Patentamt München, Nr. 0-318-216-A1).

4. Alter MJ, Coleman PJ, Alexander WJ, Kramer E, Miller JK, Mandel E, Hadler SC, Margolis HS . "Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis" . JAMA 1989 ; 262 : 1201-1205 .

5. Alter MJ, Sampliner RE . "Hepatitis C and miles to go before we sleep" . N Engl J Med 1989 ; 321 : 1538-1540 .

6. Alter MJ, Hadler SC, Judson FN, Mares A, Alexander WJ, Hu PJ, Miller JK, Moyer LA, Fields HA, Bradley DW, Margolis HS . "Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection." JAMA .1990 ; 264 : 2231-2235 .

7. Alter MJ. "Inapparent transmission of hepatitis C: footprint in the sand." Hepatology 1991 ; 14 : 389-391 .

8. Alter MJ, Margolis HD, Krawczynski K, Judson FN, Mares A, Alexander WJ, Hu PY, Miller JK, Gerber MA, Sampliner RE, Meeks EL, Beach MJ . "The natural history of community-acquired hepatitis C in the United States." N Engl J Med 1992 ; 327 : 1899-1905 .

9. Han JH, Shyamala V, Richmann KH, Brauer MJ, Irvine B, Urdea MS, Tekamp-Olson P, Kuo G, Choo Q-L, Houghton M ". Characterisation of the terminal regions of hepatitis C viral RNA: Identification of conserved sequences in the 5' untranslated region and poly(A) tails at the 3' end." Proc. Natl Acad Sci 1991 ; 88 : 1711-1715 .

10. Francki RIB, Fauquet CM, Knudson DL, Brown F . "Classification of nomenclature of viruses. Fifth report of the International Committee on Taxonomy of Viruses" . Arch Virol 1991 (Suppl 2); 223 .

11. Houghton M, Weiner A, Han J, Kuo G, Choo Q-L . "Molecular biology of the hepatitis C viruses: Implications for diagnosis, development and control of viral disease." Hepatology 1991 ; 14 : 381-388 .


63

12. Choo Q-L, Kuo G, Weiner A, Wang K-S, Overby L, Bradley D, Houghton M . "Identification of the major, parenteral non-A, non-B hepatitis agent (hepatitis C virus) using a recombinant cDNA approach" . Sem Liv Dis 1992 ; 12 : 279-288 .

13. Reed KE, Rice CM. "Molecular characterization of hepatitis C virus. " In" " Reesnick HW (Editor)": Hepatitis C Virus, 2nd revised and enlarged edition. Current Studies in Hematology and Blood Transfusion." Basel , Karger 1998 ; No 62 : 1-37 .

14. Bartenschlager R. "The NS3/4A proteinase of the hepatitis C virus: unravelling structure and function of an unusual enzyme and a prime target for antiviral therapy" . J Viral Hepat 1999 ; 6 : 165-181 .

15. Reed KE, Rice CM. "Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties" . Curr Top Microbiol Immunol 2000 ; 242 : 55-84 .

16. Choo Q-L, Richmann KH, Han JH, Berger K, Lee C, Dong C, Gallegos C, Coit D, Medina-Selby A, Barr PJ, Weiner AJ, Bradley DW, Kuo G, Houghton M. "Genetic organisation and diversity of the hepatitis C virus. " Proc Nat Acad Sci 1991 ; 88 : 2451-2455 .

17. Kato N, Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T, Shimotohno K. "Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A non-B hepatitis" . Proc Natl Acad Sci 1990 ; 87 : 9524-9528 .

18. Takamizawa A, Mori C, Fuke I, Murakami S. Fujita J, Onishi E, Andoh T, Yoshida I, Okayama H . "Structure and organisation of the hepatitis C virus genome isolated from human carriers" . J Virol 1991 ; 65 : 1105-1113

19. Okamoto H, Okada S, Sugiyama Y, Kurai K, Iizuka H, Machida A, Miyakawa Y Mayumi M . "Nucleotide sequence of the genomic RNA of hepatitis C virus isolated from a human carrier: Comparison with reported isolates for conserved and divergent regions." J Gen Virol 1991 ; 72 : 2697- 2704 .

20. Behrens SE, Tomei L, De Francesco R ". Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus." EMBO 1996 ; 15 : 12-22 .

21. Chen PJ, Lim MH, Tai KF, Liu PC, Lin CJ, Chen DS . "The Taiwanese hepatitis C virus genome: sequence determination and mapping the 5' termini of viral genomic and antigenomic RNA. " Virology 1992 ; 188 : 102-113 .

22. Ogata N, Alter HJ, Miller R, Purcell RH. "Nucleotide sequence and mutation rate of the H strain of hepatitis C virus." Proc Natl Acad Sci 1991 ; 88 : 3392-3396 .

23. Okamoto H, Okada S, Sugiyama Y, Kurai K, Iizuka H, Machida A, Miyakawa Y Mayumi M. "Nucleotide sequence of the genomic RNA of hepatitis C virus isolated from a human carrier: Comparison with reported isolates for conserved and divergent regions." J Gen Virol 1991 ;


64

72 : 2697- 2704 .

24. Okamoto H, Kurai K, Okada S-I, Yamamoto K, Lizuka H, Tanaka T, Fukuda S, Tsuda F, Mishiro S. "Full-length sequence of a hepatitis C virus genome having poor homology to reported isolates: Comparative study of four distinct genotypes" . Virology 1992 ; 188 : 331-341 .

25. Simmonds P, McOmish F, Yap PL, Chan SW, Lin CK, Dusheiko G, Saeed AA, Holmes EC. "Sequence variability in the 5' non-coding region of hepatitis C virus: Identification of a new virus type and restriction on sequence diversity" . J Gen Virol 1993 ; 74 : 661-668 .

26. Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B, Beall E, Yap PL, Kolberg J, Urdea MS . "Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region" . J Gen Virol 1993 ; 74 : 2391-2399 .

27. Simmonds P, Rose KA, Graham S, Chan S-W, McOmish F, Dow BC, Follett EAC, Yap PL, Marsden H . "Mapping of serotype-specific, immunodominant epitopes in the NS-4 region of hepatitis C virus (HCV): Use of type-specific peptides to serologically differentiate infections with HCV types 1, 2, and 3" . J Clin Microbiol 1993 ; 31 : 1493-1503 .

28. Pozzato G, Moretti M, Franzin F, Croce LS, Tiribelli C, Masayu T, Kaneko S, Unoura Kobayashi K . "Severity of liver disease with different hepatitis C viral clones." Lancet 1991 ; 338 : 509 .

29. McOmish F, Chan SW, Dow BC, Gillon J, Frame WD, Crawford RJ, Yap PL, Follett EAC, Simmonds P . "Detection of three types of hepatitis C virus in blood donors: investigation of type-specific differences in serologic reactivity and rate of alanine aminotransferase abnormalities." Transfusion 1993 ; 33 : 7-13 .

30. Takada N, Takase S, Enomoto N, Takada A, Date T ". Clinical backgrounds of the patients having different types of hepatitis C virus genomes." J Hepatol 1992 ; 14 : 35

31. Kanai K, Kako M, Okamoto H ". HCV genotypes in chronic hepatitis-C and response to interferon." Lancet 1992 ; 339 : 1543 .

32. Yoshioka K, Kakumu S, Wakita T, Ishikawa T, Itoh Y, Takayanagi M, Higashi Y, Shibata M, Morishima T. "Detection of hepatitis C virus by polymerase chain reaction and response to interferon-* therapy: Relationship to genotypes of hepatitis C virus." Hepatology 1992 ; 16 : 293-299 .

33. Berg T, König V, Küther S, Heuft HG, Wittmann G, Lobeck H, Hopf U . "Prognostic importance of hepatitis C virus genotypes for the responsiveness to interferon-alpha" Z Gastroenterol 1995 ; 33 : 426-430 .

34. Qu D, Li JS, Vitvitski L, Mechai S, Berby F, Tong SP, Bailly F, Wang QS, Martin JL, Trepo C. "Hepatitis C virus genotypes in France: comparison of clinical features of patients infected "


65

"with HCV type I and II." J Hepatol 1994 ; 21 : 70-75 .

35. Driesel G, Wirth D, Stark K, Baumgarten R, Sucker U, Schreier E. "Hepatitis C virus (HCV) genotype distribution in German isolates: studies on the sequence variability in the E2 and NS5 region." Arch Virol 1994 ; 139 : 379-388 .

36. Pistello M, Maggi F, Vatteroni L, Cecconi N, Panicucci F, Bresci GP, Gambardella L, Taddei M, Bionda A, Tuoni M, Bendinelli M. "Prevalence of hepatitis C virus genotypes in Italy." J Clin Microbiol 1994 ; 32 : 232-234 .

37. Mondelli MU, Silini E. "Clinical significance of hepatitis C virus genotypes." J Hepatol 1999 ; 31 (Suppl. 1) : 65-70 .

38. Cohen J . "The scientific challenge of hepatitis C." Science 1999 ; 285 : 26-30 .

39. Trépo C, Pradat P. "Hepatitis C virus infection in Western Europe." J Hepatol 1999 ; 31 (Suppl. 1): 80-83 .

40. Naoumov NV. "Hepatitis C virus infection in Eastern Europe. " J Hepatol 1999 ; 31 (Suppl. 1) : 84-87 .

41. Couzigou P, Richard L, Dumas F, Schouler L, Fleury H. "Detection of HCV-RNA in saliva of patients with chronic hepatitis C" . Gut 1993 ; 34 (Suppl) : S59 -S60 .

42. Van der Poel CL . "Hepatitis C virus and blood transfusion: past and present risks." J Hepatol 1999 ; 31 (Suppl. 1) : 101-106 .

43. Alter MJ. "Epidemiology of hepatitis C" . Hepatology 1997 ; 26 : 62S-65S .

44. Dienstag JL. "Sexual and perinatal transmission of hepatitis C." Hepatology 1997 ; 26 : 665 -705 .

45. Zanetti AR, Tanzi E, Newell ML. "Mother-to-Infant transmission of hepatitis C virus" . J Hepatol 1999 ; 31 (Suppl. 1) : 96-100 .

46. Thomas DL, Villano SA, Riester KA, Hershow R, Mofenson LM, Landesman SH, Hollinger FB, Davenny K, Riley L, Diaz C, Tang HB, Quinn TC. "Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. Women and infants transmission study" . J Infect Dis 1998 ; 177 : 1480-1488 .

47. Wejstal R. "Sexual transmission of hepatitis C virus" . J Hepatol 1999 ; 31 (Suppl. 1) : 92-95 .

48. Alter MJ, Mast EE . "The epidemiology of viral hepatitis in the United States" . Gastronterology Clinics of North America 1994 ; 23 : 437 .

49. Hopf U, Möller B, Küther S, Stemerovicz R, Lobeck H, Lüdtke-Handjery A, Walter E, Blum H.E, Roggendorf M, Deinhardt F. "Long-term follow-up of posttransfusion and sporadic "


66

"hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus" . J Hepatol 1990 ; 10 : 69 .

50. Alberti A, Realdi G. "Parenterally acquired non-A, non-B (type C) hepatitis" . In: McIntyre, N., J-P. Benhamou, J. Bircher, M. Rizzetto, J. Rodes (ed.): Oxford Textbook of Clinical Hepatology . Oxford University Press , Oxford (1991 ).

51. Kiyosawa K, Akahane Y, Nagata A, Koike Y, Furuta S. "Significance of blood transfusion in non-A, non-B chronic liver disease in Japan. " Vox Sanguinis 1982 ; 43 : 45 .

52. Tong MJ, El-Farra NS, Reikes AR, Co RL . "Clinical outcomes after transfusion-associated hepatitis C" . New Engl J Med 1995 ; 332 : 1463 .

53. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, Hashimoto E, Lefkowitch JH, Ludwig J, Ukuda K. "The long-term pathological evolution of chronic hepatitis C." Hepatology 1996 ; 23 : 1334 .

54. Marcellin P. "Hepatitis C: the clinical spectrum of the disease." J Hepatol 1999 ; 31 (Suppl. 1) : 9-16 .

55. Nishigushi S, Kuroki T, Nakatani S, Morimoto H, Takeda H, Nakajima S, Shiomi S, Seki S, Kobayashi K, Otani S. "Randomised trial of the effects of interferon-a on incidence of hepatocellular carcinoma in chronic active hepatitis C" . Lancet 1995 ; 346 : 1051 .

56. Resnick RH, Koff R ". Hepatitis C-related hepatocellular carcinoma. Prevalence and significance" . Arch Int Med 1993 ; 153 : 1672 .

57. Nishigushi S, Shiomi S, et al. "Prevention of hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis." Lancet 2001 ; 357 : 196-197 .

58. Davis GL, Albright JE, Cook S, Rosenberg D ". Projecting the healthcare burden from hepatitis C in the United States" . Hepatology 1998 ; 28 (No.4; Pt.2): 390A .

59. Seef LB , "Natural history of hepatitis C " Postgraduate Course 2000: Update on viral hepatitis. AASLD 2000 : 112-118 .

60. Joklik WK . "Interferons" . In: Fields, N., D. M. Knipe (Editor): Virology . Raven Press , New York 1990 ; 383 .

61. Kirchner H. "Interferons, a group of multiple lymphokines" . Springer Semin Immunpathol 1984 ; 7 : 347 .

62. Peters M. "Mechanisms of action of interferon" . Sem Liv Dis 1989 ; 9 : 5 .

63. Isaacs A, Lindenmann J . "Virus interference. I. The interferons" . Proc R Soc Lond 1957 ; 147 : 258 .


67

64. Lindenmann J . "Induction of chick interferon: procedures of the original experiments" . Method Enzymol 1981 ; 78 : 181-188 .

65. Weissmann C, Weber H. "The interferon genes" . Prog Nucleic Acid Res Mol Biol 1986 ; 33 : 251 .

66. Owerbach D, Rutter WJ, Shows TB, Gray P, Goeddel DV, Lawn RM . "Leucocyte and fibroblast interferon genes are located on human chromosome 9." Proc Natl Acad Sci USA 1981 ; 126 : 3123-3127 .

67. Seghal PB, Pfeffer LM, Tamm I. "Interferon and its inducers" . In: Carme PE, Calicuin LA (ed.): Viral Infection 1982 ; 205 .

68. Ohlsson M, Feder J, Cavalli-Sforza LL, v. Gabain A. "Close linkage of alpha and beta interferons and infrequent duplication of beta interferon in humans" . Proc Natl Acad Sci U S A 1985 ; 82 : 4473 .

69. Taniguchi T, Sakai M, Fujii-Kuriyama Y, Muramatsu M, Kobayashi S, Sudo T. "Construction and identification of a bacterial plasmid containing the human fibroblast gene sequence." Proc Jpn Acad (Ser B) 1979 ; 55 : 464 .

70. Gray PW, Goeddel DV. "Structure of the human immune interferon gene" . Nature 1982 ; 298 : 859-863 .

71. Naylor SL, Sakaguchi AY, Schows TB, Law ML, Goeddel DV, Gray PW. "Human immune interferon gene is located on chromosome 12." J Exp Med 1983 ; 157 : 1020-1027 .

72. Vilcek J, Kelker H, Le J, Yip YK. "Structure and function of human interferon-gamma" . In: Ford, R., A. Maizel (ed.): Mediators in cell growth and differentation . Raven Press , New York 1985 ; 299 .

73. Huez G, Silhol M, Lebleu B. "Microinjected interferon does not promote an antiviral response in HeLa cells." Biochem Biophys Res Commun 1983 ; 110 : 155 .

74. Vengris VE, Stollar BD, Pitha PM. "Interferon externalization by producing cell before induction of antiviral state" . Virology 1975 ; 65 : 410 .

75. Aguet M, Blanchard B. "High affinity binding of 125J-labeld mouse interferon to a special cell surface receptor: II. Analysis of binding properties" . Virology 1981 ; 115 : 249 .

76. Evans T, Secher D. "Kinetics of internalisation and degradation of surface bound interferon in human lymphoblastoid cells" . EMBO 1984 ; 3 : 2975 .

77. Pestka S. "Interferons and their actions" . Ann Rev Biochem 1987 ; 56 : 727 .

78. Stark GR, Kerr IM, Williams BRG, Silvermann RH, Schreiber RD. "How cells respond to interferons" . Annu Rev Biochem 1998 ; 67 : 227 .


68

79. Samuel CE . "Mechanisms of the aniviral action of interferons" . Proc Nucl Acid Res 1988 ; 35 : 27 .

80. Samuel CE . "Progress toward the understanding of the molecular mechanism of interferon action" . Prog Clin Biol Res 1987 ; 246 : 209 .

81. Johnston M, Torrence P. "The role of interferon-induced proteins, double stranded RNA and 2‘, 5‘-oligoadenylate in the interferon-mediated inhibition of viral translation" . In: Friedman, RM (ed) Interferon: Mechanism of production and action . Elsevier Science Publishers 1984 ; 190-297 .

82. Whitaker-Dowling P, Younger JS. "Characterization of specific kinase inhibitory factor produced by vaccinia virus which inhibits the interferon induced protein kinase" . Virology 1984 ; 137 : 171 .

83. Guttermann JU . "Cytokine therapeutics: lessons from interferon-alpha. " Proc Natl Acad Sci USA 1994 ; 91 : 1198 .

84. Sarrazin C, Zeuzem C . "Wirkungsweise von Interferonen und Nukleosidanaloga" . Verdauungskrankheiten 2000 ; 18 : 102-113 .

85. Zeuzem S, Schmidt JM, Lee J-H, Rüster B, Roth WK. "Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo." Hepatology 1996 ; 23 : 366 .

86. Lam N, Neumann A, Gretch D, Wiley T, Perelson A, Layden T ". Dose-dependent acute clearance of hepatitis genotype 1 virus with interferon alfa. " Hepatology 1997 ; 26 : 226 .

87. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. "Hepatitis C viral dynamics and the antiviral efficacy of interferon-a therapy. " Science 1998 ; 282 : 103 .

88. Diepolder HM, Hoffmann RM, Gerlach JT, Zachoval R, Jung MC, Pape GR. "Immunopathogensis of HCV infection" . In H. W. Reesink, Editor; Hepatitis C Virus , 2nd Edition 1998 ; 135 .

89. Hoffmann R, Diepolder H, Zachoval R, Zwiebel F-M, Jung M-C, Scholz S, Nitschko H, Riethmüller G, Pape GR. "Mapping of immunodominant CD4+ T lymphocyte epitopes of hepatitis C virus antigens and their relevance during the course of chronic infection." Hepatology 1995 ; 21 : 632 .

90. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Izumi N, Marumo F, Sato C. "Comparison of full-lenght sequences of interferon-sensitive and resistant hepatitis C virus 1b: Sensivity to interferon is conferred by amino acid substitutions in the NS5A region. " J Clin Invest 1995 ; 96 224 .

91. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C. "Mutations in the nonstructural protein 5A gene and response to "


69

"interferon in patients with chronic hepatitis C virus 1b infection" . N Engl J Med 1996 ; 334 : 77 .

92. Chayama K, Tsubota A, Kobayashi M, Okamoto K, Hashimoto M, Miyano Y, Koike H, et al. "Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection." Hepatology 1997 ; 25 : 745-749 .

93. Kurosaki M, Enomoto N, Murakima T, Sakuma I, Asahina Y, Yamamoto C, Ikeda T, et al. "Analysis of genotypes and amino acid residues 2209-2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy" . Hepatology 1997 ; 25 : 750-753 .

94. Zeuzem S, Lee H-J, Roth WK. "Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa" . Hepatology 1997 ;25 :740-744 .

95. Hofgärtner WT, Polyak SJ, Sullivan DG, Carithers RL, Jr., Gretch DR . "Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b. " J Med Virol 1997 ;53 :118-126 .

96. Squadrito G, Leone F, Sartori M, Nalpas B, Berthelot P, Pol S, Brechot C . "Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa. " Gastroenterology 1997 ;113 :567-572 .

97. Gale MJ, Korth MJ, Tang NM, Tan SL, Hopkins DA, Dever TE, Polyak SJ, Gretch DR, Katze MG. "Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein" . Virology 1997 ; 230 : 217 .

98. Gale MJ, Korth MJ, Katze MG. "Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: a potential mechanism of interferon resistance" . Clin Diagn Virol 1998 ; 10 : 157 .

99. Gale MJ, Blakely CM, Kwieciszewski B, Tan SL, Dosset M, Tang NM, Korth MJ, Katze MG. "Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation" . Mol Cell Biol 1998 ; 18 : 5208 .

100. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MMC. "Inhibition of the interferon-inducible kinase PKR by HCV E2 protein" . Science 1999 ; 285 : 107 .

101. Pfeffer LM, Dinarello CA, Hebermann RB, Williams BRG, Borden EC, Bordens R, Walter MR, Nagabhushan TL, Trotta PP, Pestka S. "Biological properties of recombinant a-interferons: 40th anniversary of the discovery of interferons" . Cance Res 1998 ; 58 : 2489-2499 .

102. Zoon KC, Miller D, Bekicz J, zur Nedden D, Enterline JC, Nguyen NY, Hu R. "Purification and characterization of multiple components of human lymphoblastoid interferon-a." J Biol Chem 1992 ; 1267 : 15210 .


70

103. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie AM, Peters M, Waggoner JG. "Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: a preliminary report" . N Engl J Med 1986 ; 315 : 1575 .

104. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, Carey W, Jacobsen IM, Payne J, Dienstag JL, Van Thiel DH, Tamburro C, Lefkowitch J, Albrecht J, Meschievitz C, Ortego TJ, Gibas A. "Treatment of chronic hepatitis C with recombinant interferon alfa" . N Engl J Med 1989 ; 321 : 1501 .

105. Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D, Heyraud JP, Fontanges T, Albrecht J, Meschievitz C. "Comparison of 1 or 3 MU of interferon alfa 2b and placebo in patients with chronic non-A, non-B hepatitis" . Gastroenterology 1991 ; 101 : 497 .

106. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melan M, Murray L, Waggoner J, Goodman Z, Banks SM, Hoofnagle JH. "Recombinant interferon alfa therapy for chronic hepatitis C." N Engl J Med 1989 ; 321 : 1506 .

107. Hoofnagle JH, Peters M, Mullen KD. "Randomized, controlled trial of recombinant human a-interferon in patients with chronic hepatitis C." Gastroenterology 1998 ; 95 : 1318 .

108. Hopf U, Möller B, König V, Küther S, Lobeck H, Huhn D. "Langzeitbehandlung der kryptogenen chronischen Hepatitis C mit rekombinantem Interferon alpha." Z Gastroenterol 1990 ; 28 : 453 .

109. Hopf U, Küther S, König V, Heuft HG, Berg T, Bauditz J, Soltani K, Lobeck H, Huhn D. "Langzeitbeobachtung der chronischen Hepatitis C nach Behandlung mit rekombinantem Interferon alpha-2a." Z Gastroenterol 1994 ; 32 : 425 .

110. Marcellin P, Boyer N, Giostra E, Degott C, Louronce AM, Degos F, Coppere H, Cales P, Couzigou P, Benhamou JP. "Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France." Hepatology 1991 ; 13 : 393 .

111. Patterson JL, Fernandez-Larsson R. "Molecular mechanisms of action of ribavirin" . Rev Infect Dis 1990 ; 12 : 1139 .

112. Sidwell RW, Huffman JH, Kharp L, Allen LB, Witkowski JT, Robins RK. "Broad spectrum activity of virazole: 1-beta-D-ribofuranosyl-1,2,3-triazole-3-carboxamide." Science 1972 ; 117 : 705 .

113. Ilyin GP, Langouet S, Rissel M, Delcros JG, Guillouzo A, Guguen GC. "Ribavirin inhibits protein synthesis and cell proliferation induced by mitogeic factors in primary human and rat hepatocytes." Hepatology 1998 ; 27 : 1687 .

114. Montero C, Duley JA, Fairbanks LD, McBride MB, Micheli V, Cant AC, Morgan G .


71

"Demonstration of induction of erythrocyte inosine monophosphate dehydrogenase activity in ribavirin-treated patients using a high performance liquid chromatography linked method." Clin Chem Acta 1995 ; 238 : 169 .

115. Di Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C, Swain MG, Kleiner DE, Maheaney K, Hoofnagle JH. "Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial." Ann Intern Med 1995 ; 123 : 897 .

116. Bodenheimer HC, Lindsay KL, Davis GL, Lewis IH, Thung SN, Seef KLB. "Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial." Hepatology 1997 ; 26 : 473 .

117. Dusheiko G Main J, Thomas H, Reichard O, Lee C, Dhillon A, Rassam S, Fryden A, Reesink H, Bassendine M, Norkrans G, Cuypers T, Lelie N, Telfer P, Watson J, Weegink C, Sillikens P, Weiland O. "Ribavirin treatment for patients with chronic hepatitis C: results of a placebo controlled study" . J Hepatol 1996 ; 25 : 591 .

118. Reichard O, Andersson J, Schvarcz R, Weiland O. "Ribavirin treatment for chronic hepatitis C" . Lancet 1991 ; 337 : 1058 .

119. Reichard O, Yun Z-B, Sönnerborg A, Weiland O. "Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C" . J Med Virol 1993 ; 41 : 99 .

120. Smith JP. "Treatment of chronic hepatitis C with amantadine." Dig Dis Sci 1997 ;42 :1681-87 .

121. Dolin R, Reichmann RC, Madore HP, Maynard R, Linton PN, Webber-Jones J. "A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection." N Engl J Med 1982 ;307 :580-84 .

122. Hay AJ, Wolstenholme AJ, Skehel JJ, Smith MH. "The molecular basis of the specific anti-influenza action of amantadine. " EMBO J 1985 ;4 :3021-24 .

123. Wang C, Takeuchi K, Pinto LH, Lamb RA. "Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block" . J Virol 1993 ;76 :5585-94 .

124. Martin J, Navas S, Fernández M, et al. "In vitro effect of amantadine and interferon-2a on hepatitis C virus markers in cultured peripheral blood mononuclear cells from hepatitis C virus infected patients." Antiviral Res 1999 ;42 :59-70 .

125. Brillanti S, Levantesi F, Foli M, Di Tomaso M, Bolondi L. "Amantadine and RebetronTM exert a synergistic antiviral effect on HCV replication in interferon-a non-responders with chronic hepatitis C." Gastroenterology 1999 ; 116 (Suppl 1) : 212 [Abstract].

126. Brillanti S, Foli M, Di Tomaso M, Gramantieri L, Masci C, Bolondi L. "Pilot study of triple "


72

"antiviral therapy for chronic hepatitis C in interferon alpha non-responders." Ital J Gastroenterol Hepatol 1999 ; 31 : 130-4 .

127. Brillanti S, Levantesi F, Masi L, Foli M, Bolondi L. "Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C." Hepatology 2000 ; 32 : 630-634.

128. Khalili M, Denham C, Perillo R. "Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C. " Am J Gastroenterol 2000 ; 95 : 1284-1289 .

129. Hubert IF, Lunel F, Cadranel J-F, Oberti F, Calès P. "Treatment of chronic hepatitis C with amantadine." Am J Gastroenterol 2000 ; 95 : 2316-2317 .

130. Zeuzem S., G. Teuber, U. Naumann, T. Berg, J. Raedle, S. Hartmann, U. Hopf. "Randomized, double-blind, placebo-controlled trial of interferon alfa2a with and without amantadine as initial treatment for chronic hepatitis C." Hepatology 2000 ; 32 : 835-841 .

131. Caronia S, Crossey M, Murray-Lyon I, Lypsnyi D, Main J, Thomas HC, Foster G. "A pilot study of interferon plus amantadine versus interferon alone in the treatment of chronic hepatitis C." J Hepatol 1999 ; 30 (Suppl 1) : 138 [Abstract].

132. Younossi ZM, Perillo RP. "The roles of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C." Sem Liver Dis 1999 ; 19 (Suppl 1) : 95 .

133. Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C, Miglioli M, Barbara L. "A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C." Gastroenterology 1994 ; 107 : 812 .

134. Chemello L, Cavaletto L, Bernardinello E, Guido M, Pontisso P, Alberti A. "The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C" . J Hepatol 1995 ; 23 (Suppl 2): 8 .

135. Lai MY, Kao JH, Yang PM, Wang JT, Chen PJ, Chan KW, Chu JS, Chen DS. "Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C." Gastroenterology 1996 ; 111 : 1307 .

136. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodmann ZG, Ling MH, Albrecht JK for the Hepatitis Interventional Therapy Group (HIT) . "Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. " N Engl J Med 1998 ; 339 : 1485 .

137. Reichard O, Norkrans G, Frydén A, Braconier JH, Sönnerborg A, Weiland O, for the Swedish Study Group . "Randomised, double blind, placebo-controlled trial of interferon-a-2b with and without ribavirin for chronic hepatitis C. " Lancet " " 1998 ; 351 : 83 .

138. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk G, Ideo G, Bain V, Heathcote J, Zeuzem


73

S, Trépo C, Albrecht J, for the International Hepatitis Interventional Group (IHIT). "Randomized trial of interferon a2b plus ribavirin for 48 weeks or 24 weeks versus interferon a2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus." Lancet 1998 ; 352 : 1426 .

139. Trépo C, Lindsay K, Niederau C, Schiffman M, Gordon S, Hoefs J, Schiff ER, Marcellin P, Bacon B, Fang J, Garaud J, Albrecht J, for the Hepatitis Interventional Therapy Group: "Pegylated interferon alfa-2B (Peg-Intron) monotherapy is superior to interferon-alfa-2B (Intron A) for the treatment of chronic hepatitis C [Abstract]." J Hepatol 2000 ; 32 (Suppl 2): 29 .

140. Zeuzem S, Feinmann SV, Rasenack J, Heathcote EJ, Lai M-Y, Gane E, O‘Grady J, Reichen J, Diago M, Lin A, Hoffmann J, Brunda MJ. "Peg-Interferon alfa-2a in patients with chronic hepatitis C." N Engl J Med 2000 ; 343 : 1666-1672 .

141. Heathcote EJ, Shiffmann ML, Cooksley GE, Dusheiko GM, Lee SS, Balart L, Reindollar R, Reddy RT, Wright TL, Lin A, Hoffmann J, De Pamphilis J ". Peg-Interferon alfa-2a in patients with chronic hepatitis C and cirrhosis" . N Engl J Med 2000 ; 343 : 1673-1680 .

142. Reddy KR, Wright TL, Pockros PJ, et al. "Efficacy and safety of pegylated (40-kd) interferon a-2a compared with interferon a-2a in noncirrhostic patients with chronic hepatitis C." Hepatology 2001 ; 33 : 433-438 .

143. Manns MP, McHutchison JG, Gordon S, Rustgi V, Shiffmann ML, Lee WM, Ling ML, Cort S, Albrecht JK . "Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C: 24 week treatment analysis of a multicenter, multinational phase III ransdomized controlled trial" . Hepatology 2000 ; 32 (No.4 Pt 2) : 297 [Abstract].

144. Glue P, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Jacobs S, Clement RP, Ingravallo P, Thomg W, Hong Z, Garaud JJ, Lau J. "A dose-ranging study of PEG-Intron and ribavirin in chronic hepatitis C - safety, efficacy, and virologic rationale." Hepatology 1999 ; 30 (No.4, Pt 2) : 303A.

145. Sulkowski M, Reindollar R, Yu J. "Combination therapy with Peginterferon a-2A (PEG-IFN) and ribavirin in the treatment of patients with chronic hepatitis C (CHC): a phase II open-label study [Abstract]." Hepatology 1999 ; 30 (No.4, Pt 2): 197A .

146. Benhamou JP, U. Hopf, Rizzetto M, Sanchez-Tapias JM, Braconier JH, Buhler H, Spacey B. and Non-A, non-B (C) Study Group ": Long-term lymphoblastoid interferon enhances sustained responses and improves histological activity up to 12 months post-treatment." Hepatology 1995 ; 22 : 151A .

147. Chemello L, Bonetti P, Cavaletto L, Talato F, Donadon V, Casarin P, Belussi F, Frezza M,


74

Noventa F, Pontisso P, Benvegnu L, Casarin C, Alberti A, and the TriVeneto Viral Hepatitis Group. " Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C." Hepatology 1995 ; 22 : 700 .

148. Davis J. "Prediction of response to interferon treatment of chronic hepatitis C" . J Hepatol 1994 ; 21 : 1 .

149. Kasahara A, Hayashi N, Hiramatsu N, Oshita M, Hagiwara H, Katayama K, Kato M, Masuzawa M, Yoshihara H, Kishida Y. "Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial." Hepatology 1995 ; 21 : 291 .

150. Lin R, Roach E, Zimmermann M, Strasser S, Farrell GC . "Interferon-alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicenter Australian trial. Australia Hepatitis C Study Group" . J Hepatol 1995 ; 23 : 487 .

151. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trépo C, Couzigou P, Payen JL, Sajus M, Costa JM, Vidaud M, Chaput JC , and "the Multicenter Study Group. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis." N Engl J Med 1995 ; 332 : 1457 .

152. Reichard O, Foberg U, Frydén A, Mattsson L, Norkrans G, Sönnerborg A, Wejstal R, Yun Z-B, Weiland O . "High sustained response rate and clearence of viremia in chronic hepatitis C after treatment with interferon-a2b for 60 weeks" . Hepatology 1994 ; 19 : 280 .

153. Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL, Kuo G. "Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis" . New. Engl. J. Med . 1989 ; 321 : 1494-1500 .

154. Peters T, Schlayer HJ, Preisler S, Kopp B, Berthold H, Gerok W, Rasenack J . "Frequency of hepatitis C in acute post-transfusion hepatitis after open-heart surgery: a prospective study in 1,476 patients" . J. Med. Virol. 1993 ; 39 : 139-145 .

155. Thiers V, Lunel F, Valla D, Azar N, Fretz C, Frangeul L, Huraux JM, Opolon P, Bréchot C. "Post-transfusional anti-HCV-negative non-A, non-B hepatitis (II) serological and polymerase chain reaction analysis for hepatitis C virus and hepatitis B virus" . J. Hepatol . 1993 ; 18 : 34-39 .

156. Simons JN, Leary TP, Dawson GJ, Pilot-Matias TJ, Muerhoff AS, Schlauder GG, Desai SM, Mushahwar IK . "Isolation of novel virus-like sequences associated with human hepatitis." Nature Medicine 1995 ; 1: 564-569 .

157. Linnen J, Wages Jr J, Zhang-Keck ZY, Fry KE, Krawczynski KZ, Alter H, Koonin E, Gallagher M, Alter M, Hadziyannis S, Karayiannis P, Fung K, Nakatsuji Y, Shih J W-K,


75

Young L, Piatak M Jr, Hoover C, Fernandez J, Chen S, Zou JC, Morris T, Hyams KC, Ismay S, Lifson JD, Hess G, Foung SKH, Thomas H, Bradley D, Margolis H, Kim JP. "Molecuar cloning and disease assosiation of hepatitis G virus: A transfusion-transmissible agent." Science 1996 ; 271 : 505-508 .

158. Muerhoff AS, Leary TP, Simons JN, Pilot-Matias TJ, Dawson GJ, Erker JC, Chalmers ML, Schlauder GG, Mushahwar IK . "Genomic organization of GB viruses A and B: two new members of the Flaviviridae associated with GB agent hepatitis" . J Virol 1995 ; 69 : 5621-5630 .

159. Schlauder GG, Dawson GJ, Simons JN, Pilot-Matias TJ, Gutierrez RA, Heynen CA, Knigge MF, Kurpiewski GS, Buijk SL, Leary TP. "Molecular and serologic analysis in the transmission of the GB hepatitis agents." J Med Virol 1995 ; 46 : 81-90 .

160. Simons JN, Pilot-Matias TJ, Leary TP, Dawson GJ, Desai SM, Schlauder GG, Muerhoff AS, Erker JC, Buijk SL, Chalmers M, Van Sant CL, Mushahwar IK . "Identification of two flavivirus-like genomes in the GB hepatitis agent" . Proc Natl Acad Sci USA 1995 ; 92 : 3401-3405 .

161. Kim JP, Fry KE. "Molecular characterisation of the hepatitis G virus" . J Viral Hepat 1997 ; 4 : 77-79 .

162. Muerhoff AS, Simons JN, Leary TP, et al. "Sequence heterogeneity withn the 5‘-terminal region of the hepatitis GB virus C genome and evidence for genotypes" . J Hepatol 1996 ; 25 : 379-384 .

163. Nishizawa T, Okamoto H, Konishi K, Yoshizawa H, Miyakawa Y, Mayumi M . "A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology" . Biochem Biophys Res Commun 1997 ; 241 :92-97 .

164. Okamoto H, Nishizawa T, Kato N, Ukita M, Ikeda H, Iizuka H, Miyakawa Y, Mayumi M. "Molecular cloning and characterization of a novel DNA virus (TTV) associated with posttransfuison hepatitis of unknown etiology" . Hepatol Res 1998 ; 10 :1-16 .

165. Miyata H, Tsunoda H, Kazi A, Yamada A, Khan MA, Murakami J, Kamahora T, Shiraki K, Hino S. "Identification of a novel GC-rich 113-nucleotide region to complete the circular single-stranded DNA genome of TT virus, the first human circovirus. " J Virol 1999 ; 73 : 3582-3586 .

166. Mushahwar IK, Erker JC, Muerhoff AS, Leary TP, Simons JN, Birkenmeyer LG, Chalmers ML, Pilot-Matias TJ, Dexai SM . "Molecular and biophysical characterization of TT virus: evidence for a new virus family infecting humans" . Proc Natl Acad Sci USA 1999 ; 96 : 3177-3182 .

167. Hijikata M, Takahashi K, Mishiro S. "Complete circular DNA genome of TT virus variant (isolate name Sanban) and 44 partial ORF2 sequences implicating a great degree of diversity beyond genotypes" . Virology 1999 ; 260 : 17-22 .


76

168. Okamoto H, Takahashi M, Nishizawa T, Ukita M, Fukuda M, Tsuda F, Miyakawa Y, Mayumi M. "Marked genomic heterogeneity and frequent mixed infection of TT virus demonstrated by PCR with primers from coding and noncoding regions." Virology 1999 ; 259 : 428-436 .

169. Naoumov NV, Petrova EP, Thomas MG, Williams R. "Presence of a newly described human DNA virus (TTV) in patients with liver disease. " Lancet 1998 ; 352 :195-197 .

170. Okamoto H, Akahane Y, Ukita M, Fukuda M, Tsuda F, Miyakawa Y, Mayumi M. "Fecal excretion of a nonenveloped DNA virus (TTV) associated with posttransfusion non-A-G hepatitis" . J Med Virol 1998 ; 56 :128-132 .

171. Simmonds P, Davidson F, Lycett C, Prescott LE, MacDonald DM, Ellender J, Yap PL, Ludlam CA, Haydon GH, Gillon J, Jarvis LM. "Detection of a novel DNA virus (TTV) in blood donors and blood products" . Lancet 1998 ; 352 :191-195 .

172. Nishizawa T, Okamoto H, Tsuda F, Aikawa T, Sugai Y, Konishi K, Akahane Y, Ukita M, Tanaka T, Miyakawa Y, Mayumi M . "Quasispecies of TT virus (TTV) with sequence divergence in hypervariable regions of the capsid protein in chronic TTV infection" . J Virol 1999 ; 73 : 9604-9608 .

173. Tanaka Y, Mizokami M, Orito E, Ohno T, Nakano T, Kato T, Mukaide M, Park YM, Kim BS, Ueda R. "New genotypes of TT virus (TTV) and a genotyping assay based on restriction fragment length polymorphism" . FEBS Letter 1998, 437 :201-206.

174. Okamoto H, Nishizawa T, Ukita M, Takahashi M, Fukuda M, Iizuka H, Miyakawa Y, Mayumi M. "The entire nucleotide sequence of a TT virus isolate from the United States (TUS01): comparison with reported isolates and phylogenetic analysis." Virology 1999 ; 259 : 437-448 .

175. Berg T, Kaul T, Heuft HG, Naumann U, Lobeck H, Wiedenmann B, Hopf U . "Analysis of long-term efficacy of interferon-alpha treatment in chronic hepatitis C." J Hepatol 1998 ; 28 : 511-512 .

176. Hopf U, Küther S, König V, Heuft HG, Berg T, Soltani K, Lobeck H . "Langzeitbeobachtung der chronischen Hepatitis C nach Behandlung mit rekombinanten Interferon alpha-2a." Z Gastroenterol 1994 ; 32 : 425-430 ;

177. Shindo M, Di Biscglie AM, Hoofnagle JH ". Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon" Hepatology 1992 ; 15 : 1013-1016 .

178. Reichard O, Glaumann H, Fryden A, Norkrans G, Schvarcz R, Sonnerborg A, et al. "Two-year biochemical, virological and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. " Hepatology 1995 ; 21 : 918-922.


77

179. Teuber G, Dienes HP, Meyer zum Büschenfelde KH, Gerken G. "Long-term follow-up of patients with chronic hepatitis C after interferon-alpha treatment." Digestion 1996 ; 57 : 464-471 .

180. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, et al. "Long-term improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-a therapy." Ann Intern Med 1997 ; 127 : 875-881 .

181. Tsubota T, Kumada H, Chayama K, Arase Y, Saitoh S, Koida I, Suzuki Y, Kobayashi M, Murashima N, Ikeda K . "Time course of histological changes in patients with a sustained biochemical and virological response to interferon-alpha therapy for chronic hepatitis C." J Hepatol 1997 ; 27 : 49-55 .

182. Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, Miller JL, Manns MP, Rehermann B. "Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C" . Nat Med 2000 ; 6 : 578-82 .

183. Berg T, König V, Küther S, Heuft HG, Wittmann G, Lobeck H, Hopf U. "Prognostische Relevanz der Hepatitis C Virus Genotypen für das Ansprechen auf Interferon-alpha" . Z Gastroenterol 1995 ; 33 : 426-430 ;

184. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Polquin M, Degott C, Descombes I, Le Breton V, Milotova V, Benhamou JP, Erlinger S. "Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C." Hepatology 1995 ; 22 : 1050 .

185. Yoshioka K, Higashi Y, Yamada M, Aiyama T, Takayanagi M, Tanaka K, Okumura A, Iwata K, Kakumu S . "Predictive factors in the response to interferon therapy in chronic hepatitis C." Liver 1995 ; 15 : 57 .

186. McHutchison JG, Poynard T. "Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C." Semin Liver Dis 1999 ; 19 (Suppl 1) : 57 .

187. Berg T, Hopf U, Stark, Baumgarten R, Lobeck H, Schreier E. "Distribution of hepatitis C virus genotypes in German patients with chronic hepatitis C: correlation with clinical and virological parameters." J Hepatol 1997 ; 26 : 484-491 .

188. Silini E, Botelli R, Asti M, Bruno S, Candusso ME, Brambilla S, et al . "Hepatitis C virus genotypes and risk of hepatocellular carcinoma: a case control study." Gastroenterology 1996 ; 111 : 199-205 .

189. Hatzakis A, Katsoulidou A, kaklamani E, Touloumi G, Koumantaki Y, Tassopoulos NC et al. "Hepatitis C virus 1b is the dominant genotype in HCV-related carcinogeneis: a case control "


78

"study." Int J Cancer 1996 ; 68 : 51.53 .

190. Donato F, Tagger A, Chiesa R, Ribero ML, Tomasoni V, Fasola M, et al. "For the Brecia HCC Study. Hepatitis B and C virus infection, alcohol drinking and hepatocellular carcinoma: a case control study in Italy." Hepatology 1997 ; 26 : 579-584 .

191. Naoumov NV, Chokshi S, Metivier E, Maertens G, Johnson PJ, Williams R. "Hepatitis C virus infection in the development of hepatocellular carcinoma in cirrhosis." J Hepatol 1997 ; 27 : 331-336 .

192. Féray C, Gigou M, Samuel D, Paradies V, Mishiro S, Maertens G, Reynes M, Okamoto H, Bismuth H, Bréchot C. "Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. " Gastroenterology 1995 ; 108 : 1088-1096 .

193. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, Maertens G, Williams R. "Long-term outcome of hepatitis C infection after liver transplantation" . N Engl J Med 1996 ; 334 : 815-820 .

194. Berg T, Hopf U, Bechstein WO, Müller AM, Fukumoto T, Neuhaus R, Lobeck H, Neuhaus P. "Pretransplant virological markers hepatitis C virus genotype and viremia level are not helpful in predicting the individual outcome after orthotopic liver transplantation" . Transplantation 1998 ; 66 : 225-228 .

195. "EASL International Consensus Conference on Hepatitis C:" "Consensus statement" . J Hepatol 31 Suppl 1 (1999 ) 3-8 .

196. Hopf U, Berg T, König V, Küther S, Heuft HG, Lobeck H . "Treatment of chronic hepatitis C with interferon alfa: long-term follow-up and prognostic parameters." J Hepatol 1996 ; 24 : 67-73 ;

197. Berg T, Hoffmann RM, Teuber G, Leifeld L, Lafrenz M, Baumgarten R, Spengler U, Zeuzem S, Pape GR, Hopf U . "Efficacy of a short-term ribavirin plus interferon alfa combination therapy followed by interferon alfa alone in previously untreated patients with chronic hepatitis C: a randomized multicenter trial." Liver 2000 ; 20 : 427-436 ;

198. Teuber G, Berg T, Hoffmann RM, Leifeld L, Lafrenz M, Spengler U, Pape GR, Hopf U, Zeuzem S . "Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C." Digestion 2000 , 61 : 90-97 .

199. Pawlotsky J-M, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, Dhumeaux D. "Standardization of hepatitis C virus RNA quantification" . Hepatology 2000 ; 32 : 654-659 .

200. Zeuzem S, Schmidt SM, Lee JH, Wagner M, Teuber G, Roth WK. "Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa" . Hepatology 1998 ; 28 : 245-5 2.

201. Ning Q, Brown D, Parodo J, et al. "Ribavirin inhibits viral induced macrophage production of "


79

"TNF, IL-1, the procoagulant fgl2 prothombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. " J Immunol 1998 ; 160 : 3487-93 .

202. Hultgren C, Milich DR, Weiland O, Sallberg M . "The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. " J Gen Virol 1998 ; 79 : 2381 .

203. Binder T, Berg T, Hopf U, Siegert W, Schmidt CA. "PCR-SSCP: Nonradioactive detection with biotinprimers and streptavidine-alkaline phosphatase conjugates" . BioTechniques 1995 ; 18 :780-781 .

204. Berg T, Kaul T, Naumann U, Wiedenmann B, Hopf U . "Einfluß von Ribavirin auf die Dynamik der Hepatitis C Virämie bei Interferon-alpha behandelten Patienten mit primärer Response oder Nonresponse. " Z Gastroenterol 2000 ; 38 : 1-6 .

205. Martell M, Esteban JI, Quer J, et al . "Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution." J Virol 1992 ; 66 : 3225-29

206. Forns X, Purcell RH, Bukh J . "Quasispecies in viral persistence and pathogenesis of hepatitis C virus." Trends in Microbiology 1999 ; 7 : 402-410 .

207. Kao J-H, Chen P-J, Lai M-Y, Wang T-H, Chen D-S. "Quasispecies of hepatitis C virus and genetic drift of the hypervariable region in chronic type C hepatitis" . J Infect Dis 1995 ; 172 : 261-64

208. Shindo M, Hamada K, Koya S, Arai K, Sokawa Y, Okuno T. "The clinical significance of changes in genetic heterogeneity of the hypervariable region 1 in chronic hepatitis C with interferon therapy." Hepatology 1996 ; 24 : 1018-23

209. Pawlotsky J-M, Germanidis G, Frainais P-O, et al. "Evolution of hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy. " J Virol 1999 ; 73 : 6490-99

210. Gerotto M, Sullivan DG, Polyak SJ, et al. "Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C." J Virol 1999 ; 73 : 7241-7

211. Lee JH, von Wagner M, Roth WK, Teuber G, Sarrazin C, Zeuzem S. "Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus." J Hepatol 1998 ; 29 : 29-35

212. González-Peralta RP, Liu WZ, Davis GR, Qian KP, Lau JYN. "Modulation of hepatitis C virus quasispecies heterogeneity by interferon-a and ribavirin therapy" . J Viral Hepat 1997 ; 4 : 99-106


80

213. Booth JCL, O‘Grady J, Neuberger J ", on behalf of the Royal College of Physicians of London and the British Society of Gastroenterology. Clinical guidelines on the mangement of hepatitis C." Gut 2001 ; 49 (Suppl 1) : i1-i21 .

214. Zeuzem S, Teuber G, Naumann U, Berg T, Raedle J, Hartmann S, Hopf U. "Randomised, double-blind, placebo-controlled trial of interferon Alfa-2A with and without amantadine as initial treatment for chronic hepatitis C" . Hepatology 2000 ; 32 : 835-841 .

215. Teuber G, Berg T, Naumann U, Raedle J, Brinkmann S, Hopf U, Zeuzem S. "Randomized, placebo-controlled, double-blind trial with interferon-a (IFN-a) with and without amantadine sulfate in primary IFN-a nonresponders with chronic hepatitis C" . J Viral Hepat 2001 ; 8 : 276-283 .

216. Berg T, Naumann U, Wiedenmann B, Hopf U . "Pilot study of interferon-alfa high-dose induction therapy in combination with ribavirin plus amantadine sulphate for nonresponder patients with chronic hepatitis C" . Z Gastroenterol 2001 ; 39 : 145-151 .

217. Kakumu S, Yoshioka K, Wakita T, Ishikawa T, Takayanagi M, Higashi Y . "A pilot study of ribavirin and interferon beta for the retreatment of chronic hepatitis C." Gastroenterology 1993 ; 105 : 507-12

218. Brillanti S, Migliolo M, Barbara L . "Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and nonresponders: Italia experience" . J Hepatol 1995 ; 23 (Suppl 2): 13-6

219. Schvarcz R, Yun ZB, Sonnerborg A, Weiland O . "Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone." J Med Virol 1995 ; 46 : 43-7 .

220. Schalm SW, Brouwer JT, Chemello L, et al . "Interferon-ribavirin combination therapy for chronic hepatitis C." Dig Dis Sci 1996 ; 41 (suppl) : 131-4 .

221. Bellobuono A, Mondazzi L, Tempini S, Silini E, Vicari F, Ideo G. "Ribavirin and interferon-alpha combination therapy vs. interferon-alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial" . J Viral Hepat 1997 ; 4 : 185-91

222. Wedemeyer H, Jäckel E, Wedemeyer J, et al. "Is combination therapy of chronic hepatitis C with interferon alpha and ribavirin in primary interferon nonresponders indicated? An analysis of personal experiences and review of the literature." Z Gastroenterol 1998 ; 36 : 819-27

223. Salmeron J, Ruiz-Extremera A, Torres C, et al. "Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: a randomized trial" . Liver 1999 ; 19 : 275-80

224. Andreone P, Gramenzi A, Cursaro C, et al. "Interferon-alpha plus ribavirin in chronic hepatitis "


81

"C resistant to previous interferon-alpha course: results of a randomized multicenter trial." J Hepatol 1999 ; 30 : 788-93

225. Pol S, Couzigou P, Bourliere M, et al. "A randomized trial of ribavirin and interferon-alpha in patients with chronic hepatitis C who were nonresponders to a previous treatment. Multicenter Study Group under the coordination of Necker Hospital, Paris, France." J Hepatol 1999 ;31 :1-7 .

226. Tromm A, Greving I, Griga T, Mankel K, Huppe D. "Interferon-alpha-2b + ribavirin for the treatment of chronic hepatitis C in non-responders to interferon-alpha-monotherapy" . Z Gastroenterol 2000 ; 38 : 159-64 .

227. Zeuzem S, Lee J-H, Franke A, Rüster B, Prümmer O, Herrmann G, Roth WK. "Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa." Hepatology 1998 ; 27 : 1149 .

228. Civeira M-P, Prieto J. "Early predictors of response to treatment in patients with chronic hepatitis C" . J Hepatol 1999 ; 31 (Suppl 1): 237 .

229. Roffi L, Mels GC, Antonelli G, et al. "Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: prevalence, etiology, and management." Hepatology 1995 ;21 :645-49 .

230. Milella M, Antonelli G, Santantonio T, et al. "Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C." Liver 1993 ;13 :146-50

231. Leroy V, Baud M, de Traversay C, et al. "Role of anti-interferon antobodies in breakthrough ocurrence during alpha 2a and 2b therapy in patients with chronic hepatitis C" . J Hepatol 1998 ;28 :375-81 .

232. Hoffmann RH, Berg T, Teuber G, Leifeld L, Prümmer O, Jung MC, Spengler U, Zeuzem S, Hopf U, Pape GR. "Interferon antibodies and the breakthrough phenomenon during ribavirin interferon-combination therapy and interferon-monotherapy of patients with chronic hepatitis C." Z. Gastroenterol 1999 , 37 : 715-723 .

233. Berg T, Schuff-Werner P, Hopf U. "Sustained remission of chronic hepatitis C after changing to human leucocyte interferon alfa (IFNa) in a difficult-to-treat patient with breakthrough phenomenon associated with antibodies against recombinant IFNa." Am J Gastroenterol 2001 , 96 : 612-614 .

234. Sarrazin C, Berg T, Lee J-H, Teuber G, Dietrich CF, Roth WK, Zeuzem S. "Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy" . J Hepatol 1999 ; 30 ; 1004-1013 .


82

235. Saiz JC, López-Labador FX, Ampurdanés S, Dopazo J, Forns X, Sánchez-Tapias JM, Rodés J. "The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus." J Infect Dis 1998 ;177 :839-847 .

236. Witherell GW, Beineke P. "Statistical analysis of combined substitutions in nonstructural region of hepatitis C virus and interferon response" . J Med Virol 2001 ; 63 : 8-12 .

237. Sarrazin S, Berg T, Lee J-H, Rüster B, Kronenberger B, Roth WK, Zeuzem S. "Mutations in the protein kinase-binding domain of the NS5A protein in patients infected with hepatitis C virus type 1a are associated with treatment response" . J Infect Dis 2000 ; 181 ; 432-441 .

238. Paterson M, Laxton CD, Thomas HC, Ackrill AM, Foster GR. "Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response. " Gastroenterology 1999 ; 117 : 1187-1197 .

239. Polyak SJ, Paschal DM, McArdle S, Gale MJ, Moradpur D, Gretch D. "Characterization of the effect of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-senstitive virus replication. " Hepatology 1999 ; 29 ; 1262-1271 .

240. Song J, Fuji SJ, Wang F, Itoh M, Hotta H. "The NS5A protein of hepatitis C virus partially inhibits the antiviral activity of interferon." J Gen Virol 1999 ; 80 : 879-886 .

241. Aizaki H, Saito S, Ogino T, Miyajima N, Harada T, Matsuura Y, Miyamura T, Kohase M. "Supression of interferon-induced antiviral activity in cell lines expressing hepatitis C virus proteins" . J Interferon Cytokine Res 2000 ; 20 : 1111-1120 .

242. Berg T, Mas-Marques A, Höhne M, Wiedenmann B, Hopf U, Schreier E. "Mutations in the E2-PePHD region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment. " Hepatology 2000 ; 32 : 1386-1395 .

243. Podevin P, Sabile A, Gajardo R, Delhem N, Abadie A, Lozach P-Y, Beretta L, Bréchot C. "Expression of hepatitis C virus NS5A natural mutants in a hepatocytic cell line inhibits the antiviral effect of interferon in a PKR-independent manner" . Hepatology 2001 ; 33 : 1503-1511 .

244. Tan S-L. Katze MG. "How hepatitis C virus counteracts the interferon response: the jury is still out on NS5A." Virology 2001 ; 284 : 1-12 .

245. Polyak SJ, Khabar KSA, Paschal DM, Ezelle HJ, Duverlie G, Barber GN, Levy DE, Mukaida N, Gretch DR. "Hepatitis C virus nonstructural 5A protein induces interleukin-8 leading to partial inhibition of the interferon-induced antiviral response" . J Virol 2001 ; 75 : 6095-6106 .

246. Sarrazin C, Kornetzky I, Rüster B, Lee J-H, Kronenberger B, Bruch K, Roth WK, et al. "Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response. " Hepatology 2000 ; 31 : 1360-1370 .


83

247. Chayama K, Suzuki F, Tsubota, et al. "Association of the amino acid sequence in the PKR-eIF2 phophorylation homology domain and response to interferon therapy" . Hepatology 2000 ; 32 : 1138-1144 .

248. Cochrane A, Orr A, Shaw M, Mills PR, McCruden EA. "The amino acid sequence of the PKR-eIF2alpha phosphorylation homology domain of hepatitis C virus envelope 2 protein and response to interferon alpha" . J Infect Dis 2000 ; 182 : 1515-1518 .

249. Polyak SJ, Nousbaum JB, Larson AM, Cotler S, Carithers RL, Gretch DR. "The protein kinase-interacting domain in the hepatitis C virus envelope glycoprotein-2 gene is highly conserved in genotype 1-infected patients treated with interferon" . J Infect Dis 2000 ; 182 : 397-404 .

250. Künkel U, Höhne M, Berg T, Hopf U, Kekulé AS, Frösner G, Pauli G, Schreier E. "Quality control study on the performance of hepatitis G virus (HGV) PCR" . J Hepatol 1998 ; 28 : 978-984 .

251. Heuft H-G, Berg T, Schreier E, Künkel U, Tacke M, Schwella N, Hopf U, Salama A, Huhn D. "Epidemiological and clinical aspects of hepatitis G virus (HGV) infection in blood donors and immunocompromised recipients of HGV-contaminated blood" . Vox Sang 1998 ;74 :161-167

252. Woelfle J, Berg T, Keller KM, Schreier E, Lentze MJ. "Persistent hepatitis G virus infection after neonatal transfusion" . J Pediatr Gastr Nutr 1998 ; 26 : 402-407 .

253. Woelfle J, Berg T, Bialek R, Keller KM, Effenberger W, Wagner N. "GB virus C/hepatits G virus infection in HIV-infected haemophiliac patients despite treatment with virus-inactivated coagulation factors." Arch Dis Child 1999 ; 80 :429-432 .

254. Schreier E, Höhne M, Künkel U, Berg T, Hopf U. "Hepatitis GBV-C sequences in patients infected with HCV contaminated anti-D immunoglobulin and among i.v. drug users in Germany" . J Hepatol 1996 , 25 : 385-389 .

255. Berg T, Naumann U, Fukumoto T, Bechstein WO, Neuhaus P, Lobeck H, Höhne M, Schreier E, Hopf U. "GB virus C infection in patients with chronic hepatitis B and C before and after liver transplantation" . Transplantation 1996 ; 62 : 711-714 .

256. Berg T, Dirla U, Naumann U, Heuft HG, Küther S, Lobeck H, Schreier E, Hopf U. "Responsiveness of interferon alpha treatment in patients with chronic hepatitis C coinfected with hepatitis G virus" . J Hepatol 1996 ; 25 : 763-768 .

257. Berg T, Müller AR, Platz KP, Höhne M, Bechstein WO, Hopf U, Wiedenmann B, Neuhaus P, Schreier E. "Dynamics of GB virus C viremia after liver transplantantion indicates extrahepatic tissues as the predominant site of GB virus C virus replication" . Hepatology 1999 , 29 : 245-249 .


84

258. Höhne M, Berg T, Müller AR, Schreier E. "Detection of sequences of a novel DNA virus (TTV) in German patients." J Gen Virol 1998 ; 79 : 2761-2764 .

259. Berg T, Schreier E, Heuft HG, Höhne M, Bechstein WO, Leder K, Hopf U, Neuhaus P, Wiedenmann B. "Occurrence of a novel DNA virus (TTV) infection in patients with liver diseases and its frequency in blood donors" . J Med Virol 1999 ; 59 : 117-121 .

260. Mphahlele MJ, Lau GKK, Carman WF. "HGV: the identification, biology and prevalence of an orphan virus" . Liver 1998 ; 18 : 143-155 .

261. Lefrere JJ, Roudot-Thoraval F, Morand-Joubert L, Petit JC, Lerable J, Thauvin M, Mariotti M. "Carriage of GB virus C hepatitis G virus RNA is associated with slower immunologic, virologic, and clinical progression of human immunodeficiency virus disease in coinfected persons" . J Infect Dis 1999 ; 179 : 783-789 .

262. Heringlake S, Ockenga J, Tillmann HL, et al. "GB virus C/hepatitis G virus infection: a favorable prognostic factor in human immunodeficiency virus-infected patients. " J Infect Dis 1998 ; 177 : 1723-1726 .

263. Pessoa MG, Terrault NA, Detmer J, Kolberg J, Collins M, Hassoba HM, Wright TL. "Quantitation of Hepatitis G and C viruses in the Liver: evidence that hepatitis G is not hepatotropic" . Hepatology 1998 ; 27 : 877-880 .

264. Fogeda M, Navas S, Martin J, Casqueiro M, Rodriguez E, Arocena C, Carreno V. "In vitro infection of human peripheral blood mononuclear cells by GB virus C/hepatitis G virus" . J Virol 1999 ; 73 : 4052-4061 .

265. Lefrere JJ, Ferec C, Roudot-Thoraval F, Loiseau P, Cantaloube JF, Biagini P, Mariotti M, LeGac G, Mercier B. "GBV-C/hepatitis G virus (HGV) RNA load in immunodeficient individual and in immunocompetent individuals" . J Med Virol 1999 ; 59 ; 32-37 .

266. Alter HJ: "The cloning and clinical implications of HGV and HGBV-C." New Engl J Med 1996 ; 334 : 1536-1537 .

267. Alter HJ, Nakatsuji Y, Melpolder J, Wages J, Wesley R, Shih WK, Kim JP: "The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease" . N Engl J Med 1997 ; 336 : 747-754 .

268. Alter MJ, Gallagher M, Morris T, Moyer LA, Meeks EL, Krawczynski K, Kim JP, Margolis HS: "Acute non-A-E hepatitis in the United States and the role of hepatitis G virus infection" . N Engl J Med 1997 ; 336 : 741-746 .

269. Okamura A, Yoshioka M, Kubota M, Kikuta H, Ishiko H, Kobayashi K. "Detection of a novel DNA virus (TTV) sequences in peripheral blood mononuclear cells" . J Med Virol 1999 ; 58 : 174-177 .


85

270. Lopez-Alcorocho JM, De Lucas S, Mariscal LF, Castillo I, Bartolome J, Herrero M, Manzano ML, Pardo M, Carreno V . "Detection of TTV DNA in paired serum, liver, and peripheral blood mononuclear cells from patients with chronic hepatitis" . Hepatology 1999 ; 30 (No.4, Pt 2) : 287A .

271. Rodriguez-Inigo E, Casqueiro M, Bartolome J, Ortiz-Movilla N, Lopez-Alcorocho JM, Herrero M, Manzarbeitia F, Oliva H, Carreno V. "Detection of TT virus in liver biopsies by in situ hybridization. " Hepatology 1999 ; 30 (No.4, Pt 2): 283A .

272. Umemura T, Yeo AET, Sottini A, Moratto D, Tanaka Y, Wang R Y-H, Shih J W-K, Donahue P, Primi D, Alter HJ. "SEN virus infection and its relationship to transfusion associated hepatitis." Hepatology 2001 ; 33 : 1303-1311 .


© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.

DiML DTD Version 2.0
Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML - Version erstellt am:
Tue Sep 17 17:18:48 2002